These studies were sufficiently encouraging to enter a research collaboration with Memorial Sloan Kettering Cancer Center to advance this preclinical research into phase I clinical studies of 89Zr-anti-STEAP1 uptake in metastatic castration resistant prostate cancer patients (www.clinicaltrials.gov, #NCT01774071) [19]. The gene discussed is STEAP1; the disease is Familial prostate cancer.